Noetic Fund

Noetic Fund is a Toronto-based venture capital firm launched in 2020, specializing in early-stage investments within the healthcare, psychedelic medicine, and biotech sectors. The fund focuses on emerging therapies and technologies aimed at improving mental health, addressing central nervous system disorders, and offering innovative solutions to global healthcare challenges. Noetic is particularly involved in the burgeoning field of psychedelic-based therapeutics, where they support companies working on treatments for conditions such as depression, PTSD, and substance use disorders. With its first fund, Noetic made around 20 investments, including notable companies like COMPASS Pathways, MindMed, and Cybin, all leaders in the psychedelic medicine space. They’ve continued to expand with the launch of Noetic Fund II, aiming to raise $200 million to further invest in groundbreaking therapies. Their strategy includes a long-term focus on companies developing new drug discoveries, digital health solutions, and medical devices that address unmet needs in mental and physical health. Noetic’s leadership includes seasoned venture capitalists and experts in life sciences, positioning the firm to capitalize on the growing acceptance and scientific validation of psychedelic treatments. They collaborate closely with portfolio companies, leveraging their expertise to foster sustainable growth and innovation.